ライフサイエンスコーパス: end-stage renal disease

1 ment of Diabetic nephropathy (DN) leading to End Stage Renal Disease.

2 shiga toxin mediated HUS, often resulting in end stage renal disease.

3 opathy (HIVAN) that ultimately progresses to end stage renal disease.

4 the establishment of fibrosis that leads to end stage renal disease.

5 ansplantation is the treatment of choice for end stage renal disease.

6 es leads to chronic kidney disease ending in end stage renal disease.

7 te phase and an increased risk of developing End Stage Renal Disease.

8 e of a reduced risk of future progression to end-stage renal disease.

9 is the preferred treatment for patients with end-stage renal disease.

10 at the last follow-up; no patient developed end-stage renal disease.

11 in patients with chronic kidney disease and end-stage renal disease.

12 transplantation early after the diagnosis of end-stage renal disease.

13 glycosylated hemoglobin A1c, statin use, and end-stage renal disease.

14 ted with an increased risk of posttransplant end-stage renal disease.

15 Ab-induced, self-limiting nephritis to fatal end-stage renal disease.

16 efits of using that organ for a patient with end-stage renal disease.

17 observation unit, previous randomisation, or end-stage renal disease.

18 reting myofibroblasts, ultimately leading to end-stage renal disease.

19 Glomerulonephritis is a common cause of end-stage renal disease.

20 enefits outweigh the risks of these drugs in end-stage renal disease.

21 omplication of diabetes and a major cause of end-stage renal disease.

22 nd acceleration of chronic kidney disease to end-stage renal disease.

23 ) but not in rates of amputation, stroke, or end-stage renal disease.

24 of hydroxyurea as preventative measures for end-stage renal disease.

25 sits, hospitalizations, quality of life, and end-stage renal disease.

26 stinterventional thrombosis in patients with end-stage renal disease.

27 ey disease, eGFR decline of 30% or more, and end-stage renal disease.

28 s, ranging from complete response to time to end-stage renal disease.

29 or death and 0.10 (95% CI, 0.00 to 0.21) for end-stage renal disease.

30 oth in the general population and those with end-stage renal disease.

31 rrent FSGS compared with all other causes of end-stage renal disease.

32 nt remains a major problem for patients with end-stage renal disease.

33 of klotho deficiency are similar to those of end-stage renal disease.

34 nt chronic kidney disease, eGFR decline, and end-stage renal disease.

35 ucted in 437 subjects by removing those with end-stage renal disease.

36 cumulates, the diseased kidney progresses to end-stage renal disease.

37 lled cysts in the kidneys and progression to end-stage renal disease.

38 splantation is a lifesaving intervention for end-stage renal disease.

39 glomerular disorder that often progresses to end-stage renal disease.

40 ontinuous ambulatory peritoneal dialysis for end-stage renal disease.

41 nd cardiovascular morbidity in patients with end-stage renal disease.

42 han 190 cm, obesity, and a family history of end-stage renal disease.

43 choice for patients with type 1 diabetes and end-stage renal disease.

44 epithelial cells will lead progressively to end-stage renal disease.

45 tic Nephropathy (DN) is the leading cause of end-stage renal disease.

46 isease patients, including patients with non-end-stage renal disease.

47 We enrolled adults with end-stage renal disease.

48 ng kidney donors are at an increased risk of end-stage renal disease.

49 fluid-filled kidney cysts and progression to end-stage renal disease.

50 eatment of choice for patients with terminal end-stage renal disease.

51 Few studies have focused on patients with end-stage renal disease.

52 discharge, ICU stay less than 24 hours, and end-stage renal disease.

53 ause of pediatric chronic kidney disease and end-stage renal disease.

54 r preventing progression of the condition to end-stage renal disease.

55 f death, de novo chronic kidney disease, and end-stage renal disease.

56 in heart rhythm complexity in patients with end-stage renal disease.

57 combined phenotype of severe retinopathy and end-stage renal disease.

58 and promotes the development of chronic and end-stage renal disease.

59 disease 0.78/0.90; heart failure 0.79/0.92; end-stage renal disease 0.72/0.81).

60 diovascular causes (3471 in 12 cohorts), and end-stage renal disease (1654 cases in 7 cohorts) and as

61 , respectively); the smallest decline was in end-stage renal disease (-28.3%; 95% CI, -34.6 to -21.6)

62 dds ratio [OR], 7.24; P = .015), and to have end-stage renal disease (33% vs 7%; OR, 7; P = .012).

63 e (8.9%) and all-cause mortality (8.7%) than end-stage renal disease (4.0%).

64 Six (0.2%) developed end-stage renal disease 5 to 17 years after donation, (2

65 presentation was with a rapid progression to end-stage renal disease (6 of 14) and an unusually high

66 States are required to educate patients with end-stage renal disease about all treatment options, inc

67 between the eGFR and the risks of death and end-stage renal disease across diverse populations.

68 k, Injury, Failure, Loss of kidney function, End-stage renal disease), acute kidney injury developed

69 of chronic kidney disease (CKD) that predict end-stage renal disease, acute kidney injury, cardiovasc

70 he incidences of lower-extremity amputation, end-stage renal disease, acute myocardial infarction, st

71 5% CI 1.19-1.26), and a 98% higher hazard of end-stage renal disease (adjusted hazard ratio = 1.98, 9

72 tion is associated with an increased risk of end-stage renal disease, although this outcome is uncomm

73 g of 2,806 T2D case subjects with or without end-stage renal disease and 4,265 control subjects from

74 Secondary outcomes were end-stage renal disease and acute kidney injury.

75 ure (BP) with a high prevalence of premature end-stage renal disease and cardiovascular events.

76 nd are associated with an increased risk for end-stage renal disease and cardiovascular events.

77 e the treatments of choice for patients with end-stage renal disease and end-stage liver disease, res

78 ced chronic kidney disease, as patients with end-stage renal disease and kidney transplant recipients

79 ovel drug candidates to delay progression to end-stage renal disease and limit or abrogate cardiovasc

80 e significantly more patients suffering from end-stage renal disease and more patients listed for kid

81 on has transformed the life of patients with end-stage renal disease and other chronic kidney disorde

82 OL1 were associated with the higher rates of end-stage renal disease and progression of chronic kidne

83 hrotic proteinuria and frequently results in end-stage renal disease and recurrence after kidney tran

84 Among elective patients, end-stage renal disease and reoperative status were the

85 min/1.73 m(2) and 25% decrease in eGFR), (3) end-stage renal disease, and (4) rate of kidney function

86 urinary catheters, diabetes mellitus, AIDS, end-stage renal disease, and cirrhosis), need for intens

87 , all coronary heart disease, heart failure, end-stage renal disease, and median survival.

88 mportant aspect of the care of patients with end-stage renal disease, and phosphate binders are usual

89 arable with those reported for patients with end-stage renal disease, and the prevalence of moderate

90 iabetic nephropathy (DN) is a major cause of end-stage renal disease, and therapeutic options for pre

91 Patients with chronic kidney disease and end-stage renal disease are at 5- to 10-fold higher risk

92 he crude and age-adjusted incidence rates of end-stage renal disease are estimated to be 151 and 232

93 els are 2- to 4-fold higher in patients with end-stage renal disease as compared with individuals wit

94 se, black patients are at increased risk for end-stage renal disease, as compared with white patients

95 nty-four (38.7%) patients had progression to end-stage renal disease, at a median of 1.5 (0-10.1) yea

96 ystem, we identified all adult patients with end-stage renal disease attributed to 1 of 6 GN subtypes

97 cation algorithm for adults (>/=18 years) in end-stage renal disease awaiting deceased donor kidney t

98 The number of patients with end-stage renal disease being relisted for a second kidn

99 aseline serum creatinine (MMKD-Study) and/or end stage renal disease (both studies).

100 splantation is the best treatment option for end-stage renal disease, but allograft loss remains a si

101 nts with type 1 diabetes mellitus (T1DM) and end-stage renal disease, but the indication for patients

102 0.5% of live births and are a major cause of end-stage renal disease, but their genetic aetiology is

103 Progression to end-stage renal disease can be slowed by appropriate med

104 he concentration of poverty appear to impact end-stage renal disease care and potentially access to t

105 erited nephropathy responsible for 4%-10% of end-stage renal disease cases.

106 reported using Risk, Injury, Failure, Loss, End-stage renal disease criteria, and independent factor

107 ng consensus Risk, Injury, Failure, Loss and End-Stage Renal Disease criteria.

108 idney function, loss of kidney function, and end-stage renal disease) criteria.

109 unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney fa

110 rome has a poor prognosis and often leads to end-stage renal disease development.

111 than 0, public insurance or no insurance at end-stage renal disease diagnosis, more regional acute c

112 rdiovascular events or mortality) and renal (end-stage renal disease: dialysis, transplantation, and/

113 ntation (KT) is encouraged for children with end-stage renal disease due to superior long-term graft

114 eatinine concentration and/or progression to end-stage renal disease) during follow-up in both cohort

115 y safety end point was a composite of death, end-stage renal disease, embolic events resulting in end

116 race is associated with higher incidence of End Stage Renal Disease (ESRD) among a cohort of blacks

117 with the other groups (P = 0.06) and time to end stage renal disease (ESRD) was longer in this group

118 End stage renal disease (ESRD) was not seen in R27 mice

119 Outcomes included progression to end stage renal disease (ESRD), length of stay, and mort

120 rtality (22,176 events from 28 cohorts), and end-stage renal disease (ESRD) (7644 events from 21 coho

121 Hazard ratios (HRs) of mortality and end-stage renal disease (ESRD) according to eGFR and alb

122 Few equations have been developed to predict end-stage renal disease (ESRD) after deceased donor live

123 g risk and accounting for the progression to end-stage renal disease (ESRD) after discharge.

124 Kidney donors can develop end-stage renal disease (ESRD) after donation, but the o

125 We examined the association of incident end-stage renal disease (ESRD) after liver transplantati

126 of kidney function in predicting the risk of end-stage renal disease (ESRD) after PTA remains unclear

127 of kidney function in predicting the risk of end-stage renal disease (ESRD) after PTA remains unclear

128 association between incident AF and risk of end-stage renal disease (ESRD) among adults with CKD.

129 ion between achieved blood pressure (BP) and end-stage renal disease (ESRD) among patients with chron

130 es address incidence of and risk factors for end-stage renal disease (ESRD) and proffer a new renal r

131 Obesity and end-stage renal disease (ESRD) are on the increase world

132 More than 80% of patients with end-stage renal disease (ESRD) are reported to have card

133 mate the hazard ratios (HR) of mortality and end-stage renal disease (ESRD) associated with eGFR and

134 ver-alone recipients in Group 3, the rate of end-stage renal disease (ESRD) by 3 years was 31%, versu

135 F) access improves survival in patients with end-stage renal disease (ESRD) compared with other modal

136 te (eGFR) and albuminuria, with mortality or end-stage renal disease (ESRD) differs by hypertensive s

137 Eighty-nine percent of patients with end-stage renal disease (ESRD) due to hereditary lysozym

138 familial Mediterranean fever (FMF) who reach end-stage renal disease (ESRD) due to reactive amyloidos

139 idney transplant recipients with rare native end-stage renal disease (ESRD) etiologies.

140 association between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992)

141 ciated with the risk of rapid progression to end-stage renal disease (ESRD) in a cohort of proteinuri

142 -cause mortality, cardiovascular events, and end-stage renal disease (ESRD) in a large cohort of U.S.

143 Risk of end-stage renal disease (ESRD) in kidney donors has been

144 End-stage renal disease (ESRD) is associated with T-cell

145 een AKI after CABG and the long-term risk of end-stage renal disease (ESRD) is unknown.

146 , but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.

147 first report of the incidence and causes of end-stage renal disease (ESRD) of the Turkish-Cypriot po

148 The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascu

149 umented survival advantage for patients with end-stage renal disease (ESRD) over dialysis, regardless

150 compared with dialysis, nearly one third of end-stage renal disease (ESRD) patients are not educated

151 comes for end-stage liver disease (ESLD) and end-stage renal disease (ESRD) patients awaiting transpl

152 protection of herpes zoster (HZ) vaccine in end-stage renal disease (ESRD) patients might be insuffi

153 Of 236,079 incident end-stage renal disease (ESRD) patients, 30.1% were not

154 ic malignancy incidence has been reported in end-stage renal disease (ESRD) patients, especially of f

155 een examined in the pediatric and adolescent end-stage renal disease (ESRD) population.

156 etween hepatitis C virus (HCV) infection and end-stage renal disease (ESRD) remains controversial wit

157 on between periodontal disease treatment and end-stage renal disease (ESRD) remains unclear.

158 nd others eligible for Medicare beyond their end-stage renal disease (ESRD) status yet retained the 3

159 lthough diabetes is the most common cause of end-stage renal disease (ESRD) worldwide, most people wi

160 In end-stage renal disease (ESRD), a condition characterize

161 ted diagnoses of myocardial infarction (MI), end-stage renal disease (ESRD), and non-AIDS-defining ca

162 of patients with CKD, especially those with end-stage renal disease (ESRD), are controversial.

163 ly those of black race, are at high-risk for end-stage renal disease (ESRD), but contributing factors

164 nized treatment for adults with diabetes and end-stage renal disease (ESRD), but has not been conside

165 kidney disease (CKD) to avoid precipitating end-stage renal disease (ESRD), but reliable estimates o

166 ed GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death.

167 e relationship of BMI with macroalbuminuria, end-stage renal disease (ESRD), or DKD defined as presen

168 -onset disease that is an important cause of end-stage renal disease (ESRD), which requires transplan

169 ion rate (GFR) <60 mL/min/1.73 m(2) and with end-stage renal disease (ESRD), with HP 2-2 having great

170 ECR was associated with development of end-stage renal disease (ESRD).

171 r nephrectomy increases the risk of eventual end-stage renal disease (ESRD).

172 tients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

173 2 diabetes mellitus (DM) and progression to end-stage renal disease (ESRD).

174 e of death in children and young adults with end-stage renal disease (ESRD).

175 population and compare risk of mortality and end-stage renal disease (ESRD).

176 is associated with progression of DN toward end-stage renal disease (ESRD).

177 ardiomyopathy is well known in patients with end-stage renal disease (ESRD).

178 es, have an increased risk of progression to end-stage renal disease (ESRD).

179 eficiency virus (HIV)-infected patients with end-stage renal disease (ESRD).

180 nsition from chronic kidney disease (CKD) to end-stage renal disease (ESRD).

181 nd treat AKI or impede progression to CKD or end-stage renal disease (ESRD).

182 on screening for individual risk factors for end-stage renal disease (ESRD).

183 in adults, and one-third of patients develop end-stage renal disease (ESRD).

184 of genetic variants with IgA nephropathy and end-stage renal disease (ESRD, n = 100).

185 response (P < .009), most of whom developed end-stage renal disease (ESRD; P = .005).

186 modify the subsequent risk of progression to end-stage-renal disease (ESRD) or all-cause mortality (A

187 d diabetic nephropathy (macroalbuminuria and end-stage renal disease [ESRD]).

188 e endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD], doubling of serum creati

189 rvival rate) compared with 79.0% for an age, end-stage renal disease etiology, and PRA matched group

190 incident, adult (18-69 years) patients with end-stage renal disease from 308 Georgia dialysis facili

191 est current option in care for patients with end-stage renal disease, has shown a static growth in ap

192 In conclusion, although many patients with end stage renal disease have received transplants throug

193 Chronic renal failure and end-stage renal disease have emerged as particularly str

194 e used (recipients' age, cause and length of end-stage renal disease, hemoglobin, albumin, selected c

195 prevalence of 6% to 40% among patients with end-stage renal disease, hepatitis C virus (HCV) infecti

196 In end-stage renal disease, high FGF-23 levels are associat

197 s (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolera

198 Female sex, diabetic end-stage renal disease, history of a previous transplan

199 1]), male sex (HR, 1.21; 95% CI, 1.12-1.31), end-stage renal disease (HR, 1.66; 95% CI, 1.41-1.95), s

200 PPI use also associated with development of end-stage renal disease (HR, 2.40; 95% CI, 0.76-7.58) an

201 clerosis (FSGS), the second leading cause of end stage renal disease in children, appears to be incre

202 ng-term follow-up of donors has demonstrated end-stage renal disease in 0.6% at 25 years.

203 IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-

204 risk of cardiovascular events in 14 studies, end-stage renal disease in 3 studies, and prolonged hosp

205 tified 4214 patients with LN as the cause of end-stage renal disease in a retrospective cohort of 150

206 -1 (APOL1) gene variants are associated with end-stage renal disease in African Americans (AAs).

207 ey transplantation (KT) is the treatment for end-stage renal disease in appropriate HIV-positive indi

208 ases constitute the most important cause for end-stage renal disease in children and adolescents.

209 The increase in the prevalence of end-stage renal disease in developed countries and the s

210 result of longer survival, the prevalence of end-stage renal disease in HIV is increasing.

211 essive cystogenesis and typically leading to end-stage renal disease in midlife.

212 Membranous nephropathy leads to end-stage renal disease in more than 20% of patients.

213 itis, is the most common cause of hereditary end-stage renal disease in the first three decades of li

214 All patients with end-stage renal disease in the United States without pri

215 retrospective analysis of all patients with end-stage renal disease in the US Renal Data System who

216 d phenotype of proliferative retinopathy and end-stage renal disease in U.K.-R.O.I. (odds ratio [OR]

217 exposure; adults with chronic liver disease, end-stage renal disease (including hemodialysis patients

218 ring immunosuppressive therapy, persons with end-stage renal disease (including hemodialysis patients

219 ng hemodialysis via fistula in patients with end-stage renal disease irrespective of race/ethnicity.

220 s shortcoming on mortality for patients with end-stage renal disease is enormous.

221 ase, chronic kidney disease progression, and end-stage renal disease is not clear.

222 -specific humoral responses in patients with end-stage renal disease is poorly documented.

223 FSGS as a cause of pediatric end-stage renal disease leading to transplantation is on

224 e, peripheral vascular disease, and cause of end-stage renal disease listed as other.

225 nts with type 1 diabetes mellitus (T1DM) and end-stage renal disease may receive a simultaneous pancr

226 fect burden, especially its association with end-stage renal disease, may be less than many have surm

227 han men were being treated with dialysis for end-stage renal disease merits detailed further study, a

228 In patients with end-stage renal disease, multiple easily determined echo

229 ients (acute rejection [n=2], progression to end-stage renal disease [n=2], poor venous status [n=1],

230 or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, an

231 ensity lipoprotein (HDL) in individuals with end-stage renal disease on dialysis (ESRD-HD).

232 0 to 60, glomerular filtration rate <30, and end-stage renal disease on dialysis had a higher risk of

233 In the 243 matched pairs of patients with end-stage renal disease on hemodialysis, PCI was associa

234 A 74-year-old woman with end-stage renal disease on maintenance hemodialysis pres

235 tudy, the primary outcome was a composite of end-stage renal disease or a doubling of the serum creat

236 filtration rate (eGFR) and the composite of end-stage renal disease or a reduction of 50% in the eGF

237 Endpoints of survival analysis were renal (end-stage renal disease or death) and cardiovascular eve

238 We excluded patients with end-stage renal disease or solid organ transplants becau

239 ers where differences reflect the effects of end-stage renal disease or transplantation.

240 osite primary outcome was the time to death, end-stage renal disease, or a 50% reduction from the bas

241 tent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease.

242 least 1 of mortality, cardiovascular events, end-stage renal disease, or length of hospital stay.

243 Risks for mortality, end-stage renal disease, or other clinical outcomes did

244 as a sustained doubling of serum creatinine, end-stage renal disease, or renal death.

245 ation is the optimal treatment for pediatric end stage renal disease patients to avoid increased morb

246 We retrospectively studied adult-HUS end-stage renal disease patients (n = 559) placed on the

247 e for peripheral B cells, in 101 consecutive end-stage renal disease patients admitted for transplant

248 ta System Medicare-linked data on waitlisted end-stage renal disease patients between 2005 and 2009 w

249 seful for detecting occult infection foci in end-stage renal disease patients undergoing MHD.

250 Sixty-seven consecutive end-stage renal disease patients underwent live-donor ro

251 dies were cohort studies that analyzed adult end-stage renal disease patients with hepatitis C virus

252 is widely used in chronic kidney disease and end-stage renal disease patients with hyperphosphatemia.

253 transplantation is an attractive option for end-stage renal disease patients with type 1 diabetes.

254 mpatible living-donor kidney transplants for end-stage renal disease patients with willing but incomp

255 med along with kidney transplant in diabetic end-stage renal disease patients.

256 in the year post-KT for older versus younger end-stage renal disease patients.

257 During the end-stage renal disease phase at the time of transplant,

258 d rivaroxaban use in the atrial fibrillation-end-stage renal disease population has steadily risen wh

259 End-stage renal disease (PR = 1.41; 95% CI: 1.21-1.63; P

260 vascular outcomes, composite renal outcomes, end-stage renal disease, quality of life, physical funct

261 enal transplant recipients with aHUS-related end-stage renal disease received eculizumab: 10 from day

262 e of W. virosa sepsis in a young female with end-stage renal disease, report three additional cases o

263 housands of fluid-filled cysts, resulting in end-stage renal disease requiring dialysis or kidney tra

264 lop chronic kidney disease, and some develop end-stage renal disease, requiring renal replacement the

265 A 50-year-old woman with end-stage renal disease secondary to autosomal dominant

266 In HNF1B patients who reach end-stage renal disease, single kidney transplantation (

267 In patients with both type 1 diabetes and end-stage renal disease, SPK recipients had similar prog

268 Subgroup analysis of end-stage renal disease status failed to reveal any asso

269 ors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease Study.

270 older age, diabetes mellitus as the cause of end-stage renal disease, surgery during index hospitaliz

271 orbidity, kidney function) and completed the end-stage renal disease symptom checklist (perceived sid

272 and medical (CKD-EPI) data and completed the End-Stage Renal Disease Symptom Checklist (perceived sid

273 ection are at higher risk for progression to end-stage renal disease than those who have chronic kidn

274 yl-CoA mutase (MUT), is often complicated by end stage renal disease that is resistant to conventiona

275 lternative for type 1 diabetic patients with end-stage renal disease, the management of patients who

276 In addition to end-stage renal disease, the persistence of the monoclon

277 In patients with end-stage renal disease, the prevalence of acquired risk

278 nt of type 1 diabetes (T1D) in patients with end-stage renal disease, the role of pancreas transplant

279 .e., older than 65 years of age), such as in end-stage renal disease, this therapy has not been optim

280 In most patients who develop end-stage renal disease, transplantation is the renal re

281 from the ongoing Time to Reduce Mortality in End Stage Renal Disease Trial, a large cluster-randomize

282 n: mixed cryoglobulinemia, chronic kidney or end-stage renal disease, type 2 diabetes, B-cell lymphom

283 treatment, and outcomes of individuals with end-stage renal disease undergoing dialysis might reveal

284 Patients with end-stage renal disease undergoing maintenance hemodialy

285 parallel-group study randomized adults with end-stage renal disease undergoing primary kidney transp

286 Individuals were observed from diagnosis of end-stage renal disease until first hospitalization for

287 Patients with end-stage renal disease use the emergency department (ED

288 An increased risk of end-stage renal disease was associated with an IQR incre

289 However, compared with placebo, end-stage renal disease was significantly less likely af

290 lization, device explant, and progression to end-stage renal disease were assessed using Fine-Gray mo

291 le; age, 44 +/- 12 years [mean +/- SD]) with end-stage renal disease were followed for 3.1 +/- 1.8 ye

292 l outcomes (doubling of serum creatinine and end-stage renal disease) when used as an adjunct to angi

293 increased risk of cardiovascular disease and end-stage renal disease, which are potentially preventab

294 For patients with end-stage renal disease who are not candidates for fistu

295 ta suggest that morbidly obese patients with end-stage renal disease who undergo LSG to improve trans

296 years or younger without preoperative AKI or end-stage renal disease who were undergoing cardiac surg

297 Most patients with end-stage renal disease will develop hyperparathyroidism

298 betic nephropathy (DN) is the major cause of end-stage renal disease worldwide.

299 yndrome in adults and a significant cause of end-stage renal disease, yet current therapies are nonsp

300 ohorts, and three pharmacokinetic studies in end-stage renal disease, yielding a very low quality of